Abstract
Corrigendum to "Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy" [Euro. J. Med. Chem. (2024) 116765
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have